Innovent Biologics, Inc. (HKG:1801)
Hong Kong
· Delayed Price · Currency is HKD 50.25
+0.40 (0.80%)
Apr 3, 2025, 4:08 PM HKT
Innovent Biologics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Operating Revenue | 9,422 | 6,206 | 4,556 | 4,270 | 3,844 | Upgrade
|
| Revenue | 9,422 | 6,206 | 4,556 | 4,270 | 3,844 | Upgrade
|
| Revenue Growth (YoY) | 51.82% | 36.21% | 6.71% | 11.08% | 266.94% | Upgrade
|
| Cost of Revenue | 2,412 | 1,807 | 1,382 | 1,224 | 771.82 | Upgrade
|
| Gross Profit | 7,010 | 4,399 | 3,175 | 3,045 | 3,072 | Upgrade
|
| Selling, General & Admin | 5,085 | 3,851 | 3,426 | 3,426 | 1,778 | Upgrade
|
| Research & Development | 2,681 | 2,112 | 2,871 | 2,323 | 1,851 | Upgrade
|
| Operating Expenses | 7,766 | 5,963 | 6,297 | 5,749 | 3,629 | Upgrade
|
| Operating Income | -755.87 | -1,564 | -3,123 | -2,703 | -557.19 | Upgrade
|
| Interest Expense | -67.65 | -98.62 | -101.7 | -62.46 | -68.35 | Upgrade
|
| Interest & Investment Income | 423.45 | 452.84 | 189.54 | 151.76 | 116.1 | Upgrade
|
| Earnings From Equity Investments | -41.01 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 130.28 | 60.82 | 752.05 | -198.75 | -509.74 | Upgrade
|
| Other Non Operating Income (Expenses) | 76.13 | 90 | 107.32 | 46.78 | 130.69 | Upgrade
|
| EBT Excluding Unusual Items | -234.67 | -1,059 | -2,176 | -2,766 | -888.49 | Upgrade
|
| Gain (Loss) on Sale of Investments | 179.03 | 30.81 | 5.1 | 125.02 | 30.98 | Upgrade
|
| Gain (Loss) on Sale of Assets | -22.99 | -0.95 | 0.06 | -0.71 | -1.2 | Upgrade
|
| Asset Writedown | - | -115.36 | - | - | - | Upgrade
|
| Pretax Income | -78.62 | -1,144 | -2,170 | -2,642 | -858.71 | Upgrade
|
| Income Tax Expense | 16.01 | -116.5 | 8.8 | 87.04 | 139.71 | Upgrade
|
| Earnings From Continuing Operations | -94.63 | -1,028 | -2,179 | -2,729 | -998.42 | Upgrade
|
| Net Income | -94.63 | -1,028 | -2,179 | -2,729 | -998.42 | Upgrade
|
| Net Income to Common | -94.63 | -1,028 | -2,179 | -2,729 | -998.42 | Upgrade
|
| Shares Outstanding (Basic) | 1,627 | 1,560 | 1,490 | 1,456 | 1,357 | Upgrade
|
| Shares Outstanding (Diluted) | 1,627 | 1,560 | 1,490 | 1,456 | 1,357 | Upgrade
|
| Shares Change (YoY) | 4.35% | 4.67% | 2.37% | 7.27% | 15.23% | Upgrade
|
| EPS (Basic) | -0.06 | -0.66 | -1.46 | -1.87 | -0.74 | Upgrade
|
| EPS (Diluted) | -0.06 | -0.66 | -1.46 | -1.88 | -0.74 | Upgrade
|
| Free Cash Flow | - | -971.58 | -2,816 | -3,090 | -796.71 | Upgrade
|
| Free Cash Flow Per Share | - | -0.62 | -1.89 | -2.12 | -0.59 | Upgrade
|
| Gross Margin | 74.40% | 70.89% | 69.67% | 71.32% | 79.92% | Upgrade
|
| Operating Margin | -8.02% | -25.20% | -68.54% | -63.31% | -14.50% | Upgrade
|
| Profit Margin | -1.00% | -16.56% | -47.83% | -63.91% | -25.97% | Upgrade
|
| Free Cash Flow Margin | - | -15.65% | -61.80% | -72.38% | -20.73% | Upgrade
|
| EBITDA | -480.28 | -1,288 | -2,878 | -2,538 | -489.2 | Upgrade
|
| EBITDA Margin | -5.10% | -20.76% | -63.16% | -59.44% | -12.73% | Upgrade
|
| D&A For EBITDA | 275.6 | 275.6 | 245.09 | 165.4 | 67.98 | Upgrade
|
| EBIT | -755.87 | -1,564 | -3,123 | -2,703 | -557.19 | Upgrade
|
| EBIT Margin | -8.02% | -25.20% | -68.54% | -63.31% | -14.50% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.